Nat Med: What is the effect of tumor infiltrating lymphocyte treatment for patients with anti-PD-1 drug-resistant metastatic lung cancer?

Adoptive cell therapy using tumor infiltrating lymphocytes (TIL) has been shown to be useful for the treatment of melanoma, but this therapy has not been previously evaluated in metastatic non-small cell lung cancer
.

Recently, the top medical journal Nature Medicine published a research article.
Researchers conducted a single-group open-label phase 1 trial (NCT03215810) in 20 patients with advanced non-small cell lung cancer who received nivolumab monotherapy.
)
.
The primary endpoint of the study is safety, and secondary endpoints include objective response rate, duration of response, and T cell persistence

Autologous TIL is amplified in vitro from minced tumors cultured with interleukin-2
.
The patient received cyclophosphamide and fludarabine, TIL infusion, and interleukin-2 treatment, followed by nivolumab maintenance therapy

Adverse events arising from treatment

Of the 13 patients evaluated, 3 patients have confirmed remission, 11 patients have reduced tumor burden, and the median best change is 35%
.
Two patients achieved sustained complete remission after 1.

It can be seen that autologous TIL cell therapy is generally safe and clinically active, and may be used as a new treatment for patients with metastatic lung cancer
.

Original source:

Benjamin C.